Results 151 to 160 of about 9,404 (185)
Some of the next articles are maybe not open access.
SLEEP
Abstract Introduction The Epworth Sleepiness Scale (ESS) is a commonly used 8-item patient-reported outcome measure for excessive daytime sleepiness. While aggregate data are typically presented, individual domains vary in clinical significance.
Heidy Merius +5 more
openaire +1 more source
Abstract Introduction The Epworth Sleepiness Scale (ESS) is a commonly used 8-item patient-reported outcome measure for excessive daytime sleepiness. While aggregate data are typically presented, individual domains vary in clinical significance.
Heidy Merius +5 more
openaire +1 more source
The American journal of cardiology, 1998
We performed a multicenter, open-label study to determine the long-term safety and efficacy of a new extended-release once-a-night niacin preparation, Niaspan, in the treatment of hypercholesterolemia. Niaspan, 0.5 to 3.0 g once a night at bedtime, was used alone or in combination with a statin (inhibitor of hydroxymethylglutaryl coenzyme A reductase),
J R, Guyton +5 more
openaire +1 more source
We performed a multicenter, open-label study to determine the long-term safety and efficacy of a new extended-release once-a-night niacin preparation, Niaspan, in the treatment of hypercholesterolemia. Niaspan, 0.5 to 3.0 g once a night at bedtime, was used alone or in combination with a statin (inhibitor of hydroxymethylglutaryl coenzyme A reductase),
J R, Guyton +5 more
openaire +1 more source
LONG-TERM SAFETY OF ONCE-NIGHTLY SODIUM OXYBATE: INTERIM ANALYSIS OF DATA FROM RESTORE
Chest, 2022THOMAS P STERN +7 more
openaire +1 more source
SLEEP
Abstract Introduction Once-nightly sodium oxybate (ON-SXB; LUMRYZ™) is approved to treat excessive daytime sleepiness and cataplexy in adult and pediatric patients ≥7 years of age with narcolepsy. The REFRESH study assesses the clinical effectiveness, patient satisfaction, and safety of ON-SXB for the
Sarah Meskill +9 more
openaire +1 more source
Abstract Introduction Once-nightly sodium oxybate (ON-SXB; LUMRYZ™) is approved to treat excessive daytime sleepiness and cataplexy in adult and pediatric patients ≥7 years of age with narcolepsy. The REFRESH study assesses the clinical effectiveness, patient satisfaction, and safety of ON-SXB for the
Sarah Meskill +9 more
openaire +1 more source
SLEEP
Abstract Introduction A novel once-nightly formulation of sodium oxybate (ON-SXB; LUMRYZ™) was investigated in patients with narcolepsy type 1 (NT1) and 2 (NT2) in the phase 3 REST-ON trial (NCT02720744).
Luis Ortiz +7 more
openaire +1 more source
Abstract Introduction A novel once-nightly formulation of sodium oxybate (ON-SXB; LUMRYZ™) was investigated in patients with narcolepsy type 1 (NT1) and 2 (NT2) in the phase 3 REST-ON trial (NCT02720744).
Luis Ortiz +7 more
openaire +1 more source
Pneumologie (Stuttgart, Germany), 1992
Many patients with asthma often experience a deterioration of symptoms at night and in the early morning resulting in sleep disruption and possibly impaired daily performance. A bronchodilator agent which exerts its maximal effect overnight to control nocturnal symptoms, without a worsening of the disease during the daytime, should improve the ...
V W, Steinijans +4 more
openaire +1 more source
Many patients with asthma often experience a deterioration of symptoms at night and in the early morning resulting in sleep disruption and possibly impaired daily performance. A bronchodilator agent which exerts its maximal effect overnight to control nocturnal symptoms, without a worsening of the disease during the daytime, should improve the ...
V W, Steinijans +4 more
openaire +1 more source
SLEEP
Abstract Introduction In a disproportionality analysis (Merino D, et al. J Clin Med. 2022;11:3890), sodium oxybate (SXB) treatment was associated with sleep-related eating disorder (SRED), a parasomnia characterized by somnambulism and compulsive eating. Immediate-release twice-nightly oxybate (TN-OXB)
openaire +1 more source
Abstract Introduction In a disproportionality analysis (Merino D, et al. J Clin Med. 2022;11:3890), sodium oxybate (SXB) treatment was associated with sleep-related eating disorder (SRED), a parasomnia characterized by somnambulism and compulsive eating. Immediate-release twice-nightly oxybate (TN-OXB)
openaire +1 more source
SLEEP
Abstract Introduction Once-nightly sodium oxybate (ON-SXB; LUMRYZ™) demonstrated efficacy in treating narcolepsy symptoms, including disrupted nighttime sleep (DNS), in the phase 3 REST-ON trial (NCT02720744). This post hoc analysis assessed ON-SXB efficacy on DNS across various participant subgroups.
Yves Dauvilliers +7 more
openaire +1 more source
Abstract Introduction Once-nightly sodium oxybate (ON-SXB; LUMRYZ™) demonstrated efficacy in treating narcolepsy symptoms, including disrupted nighttime sleep (DNS), in the phase 3 REST-ON trial (NCT02720744). This post hoc analysis assessed ON-SXB efficacy on DNS across various participant subgroups.
Yves Dauvilliers +7 more
openaire +1 more source
SLEEP
Abstract Introduction Once-nightly sodium oxybate (ON-SXB; LUMRYZ™) is an extended-release formulation of sodium oxybate that eliminates the second, middle-of-the-night dose required by immediate-release twice-nightly oxybate (TN-OXB) formulations.
Sally Ibrahim +7 more
openaire +1 more source
Abstract Introduction Once-nightly sodium oxybate (ON-SXB; LUMRYZ™) is an extended-release formulation of sodium oxybate that eliminates the second, middle-of-the-night dose required by immediate-release twice-nightly oxybate (TN-OXB) formulations.
Sally Ibrahim +7 more
openaire +1 more source